The Half-Life of Plasmic Degradation Products of Human Fibrinogen in Rabbits

N Ardaillou; L Dray; A. Z Budzynski; V. J Marder; M. J Larrieu

doi:10.1055/s-0038-1649220

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1977; 37(02): 201-209
DOI: 10.1055/s-0038-1649220

Original Article

Schattauer GmbH

The Half-Life of Plasmic Degradation Products of Human Fibrinogen in Rabbits

Autoren

N Ardaillou

¹Department of Coagulation (U.143, I.N.S.E.R.M.), Institut de Pathologie Cellulaire, Hôpital de Bicêtre, 94270 Le Kremlin-Bicêtre, France
L Dray

¹Department of Coagulation (U.143, I.N.S.E.R.M.), Institut de Pathologie Cellulaire, Hôpital de Bicêtre, 94270 Le Kremlin-Bicêtre, France
A. Z Budzynski

^*Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania
V. J Marder

^*Department of Medicine and the Specialized Center of Research in Thrombosis, Temple University Health Sciences Center, Philadelphia, Pennsylvania
M. J Larrieu

¹Department of Coagulation (U.143, I.N.S.E.R.M.), Institut de Pathologie Cellulaire, Hôpital de Bicêtre, 94270 Le Kremlin-Bicêtre, France

Abstract

als PDF herunterladen

Summary

Human fibrinogen and purified plasmic degradation fragments X (stages 1 and 2), D and E were labelled with 125-1 using the lactoperoxidase method. The chromatographic, elec-trophoretic and immunologic properties of the labelled proteins were found to be similar to those of non-labelled fragments. All the degradation products diffused rapidly (T½ 0.27–0.75 hours) from the intravascular space of rabbits, as compared with fibrinogen (4.26 hours). In addition, the metabolic half-life was found to be 49.3 hours for fibrinogen, as compared with only 5.1, 6.1, 2.3 and 1.4 for fragments X (stage 1), X (stage 2), D and E, respectively. The metabolic half-life roughly reflects the molecular size of the degradation products.

PDF (1486 kb)

Referenzen

References
1 Alkjaersig N, Fletcher A.P, Sherry S. Pathogenesis of the coagulation defect developing during pathological plasma proteolytic (“fibrinolytic”) states. II. The significance mechanism and consequences of defective fibrin polymerization. Journal of Clinical Investigation 1962; 41: 917
2 Ardaillou N, Larrieu M.J. In vitro studies of radio-iodinated fibrinogen. Comparison of the ICI and enzymatic methods. Thrombosis Research 1974; 5: 327
3 Ardaillou N, Sraer J.D, Beaufils P. Fibrinogen kinetics in chronic renal failure of various causes. Biomedicine 1974; 21: 49
4 Atencio A.C, Bailey H.R, Reeve E.B. Studies on the metabolism and distribution of fibrinogen in young and older rabbits. I. Methods and models. Journal of Laboratory and Clinical Medicine 1965; 66: 1
5 Budzynski A.J, Marder V.J, Shainoff J.R. Structure of plasmic degradation products of human fibrinogen. The Journal of Biological Chemistry 1974; 249: 2294
6 Catanzaro A, Edgington T.S. The in vivo behavior of the terminal derivatives of fibrinogen and fibrin cleaved by plasmin. Journal of Laboratory and Clinical Medicine 1974; 83: 458
7 Collen D, Tytgatt G.N, Claeys H, Piessens R. Metabolism and distribution of fibrinogen. I. Fibrinogen turnover in physiological conditions in humans. British Journal of Haematology 1972; 22: 681
8 Haynes O.A, Sherman L.A. In vivo behavior of fibrinogen fragment D in experimental renal, hepatic and reticuloendothelial dysfunction. American Journal of Pathology 1973; 71: 219
9 Jamieson G.A, Gaffney P.J. Heterogeneity of fibrin polymerization inhibitor. Biochimica et Biophysica Acta 1966; 121: 217
10 Jamieson G.A, Gaffney P.J. Nature of the high molecular weight fraction of fibrinolytic digests of human fibrinogen. Biochimie et Biophysica Acta 1968; 154: 96
11 Latallo Z.S, Budzynski A.Z, Lipinski B, Kowalski E. Inhibition of thrombin and fibrin polymerization. Two activities derived from plasmin digested fibrinogen. Nature 1964; 203: 1184
12 Larrieu M.J, Rigollot C, Marder V.J. Comparative effects of fibrinogen degradation Fragments D and E on coagulation. British Journal of Haematology 1972; 22: 719
13 McFarlane A.S, Todd D, Cromwell S. Fibrinogen catabolism in humans. Clinical Science 1964; 26: 415
14 Marder V.J, Budzynski A.Z. The structure of the fibrinogen degradation products. In: Spaet T. (Edit.) Progress in Hemostasis and Thrombosis 1974; vol. 2: p. 141
15 Marder V.J, James H.L, Sherry S. The purification of fibrinogen degradation products by Pevikon block electrophoresis. Thrombosis Diathesis Haemorrhagica 1969; a 22: 234
16 Marder V.J, Shulman N.R, Carroll W.R. High molecular weight derivatives of human fibrinogen produced by plasmin. I. Physiochemical and immunological characterization. Journal of Biological Chemistry 1969; b 244: 2111
17 Miyachi Y, Vaitukaitis J.L, Nieschlag E, Lipsett M.B. Enzymatic radioiodination of gonadotropins. Journal of Clinical Endocrinology and Metabolism 1972; 34: 23
18 Mosesson M.W. Fibrinogen catabolic path ways. Seminars in Thrombosis and Hemostasis 1974; 1: 63
19 Otis P.T, Rapaport S.I. Failure of fibrinogen degradation products to increase plasma fibrinogen in rabbits. Proceedings of the Society for Experimental Biology and Medicine 1973; 144: 124
20 Piessens R, Collen D, Tytgatt G.N. Computer analysis of fibrinogen tracer data. Computer and Biomedical Research 1971; 4: 585
21 Ratnoff O.D, Menzie A. A new method for the determination of fibrinogen in small samples of plasma. Journal of Laboratory and Clinical Medicine 1951; 37: 316
22 Regoeczi E. Iodine-labelled fibrinog: A review. British Journal of Haematology 1971; 20: 649
23 Scheidegger J.J. Une microméthode de l’immunoélectrophorèse. Internal Archives of Allergy and applied immunology 1955; 7: 103
24 Sherman L.A. Fibrinogen turnover: Demonstration of multiple pathways of catabolism. Journal of Laboratory and Clinical Medicine 1972; 79: 710
25 Tranqui-Pouit L, Marder V.J, Suscillon M, Budzynski A.Z, Hudry-Clergeon G. Electron microscopic studies of plasmic degradation products of fibrinogen. Biochimica et Biophysica Acta 1975; 400: 189
26 Tytgatt G.N, Collen D, Verstraete M. Metabolism of fibrinogen in cirrhosis of the liver. Journal of Clinical Investigation 1971; 50: 1690
27 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sul-fate-polyacrylamide gel electrophoresis. Journal of Biological Chemistry 1969; 244: 4406